Glypvilo

Glypvilo is a prescription oral tablet that contains the active ingredient vildagliptin. It is marketed in the European Union and belongs to the DPP‑4 inhibitor class of antidiabetic medicines, used to improve blood glucose control in adults with type 2 diabetes. The medication works by inhibiting the enzyme dipeptidyl peptidase‑4, which raises levels of incretin hormones and helps regulate insulin and glucagon secretion. It is available only with a doctor's prescription.

Vildagliptin under the brand name Glypvilo is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise, and other oral antidiabetic agents do not provide adequate glycemic control.

- As monotherapy for patients newly diagnosed with type 2 diabetes who require additional glucose lowering. - In combination with metformin when metformin alone does not achieve target HbA1c. - Added to a sulfonylurea regimen to enhance insulin secretion in patients inadequately controlled. - Used together with insulin in patients who need further reduction of fasting glucose. - Considered for patients with mild to moderate renal impairment when dose adjustment is appropriate.

Like other DPP‑4 inhibitors, Glypvilo may cause a range of adverse reactions. These are usually mild to moderate, but some can be serious and require medical attention.

Common: - Upper respiratory tract infection, such as nasopharyngitis. - Headache, often mild and transient. - Dizziness or light‑headedness, especially after initiating therapy. - Gastrointestinal discomfort, including nausea or abdominal pain.

Serious: - Pancreatitis, presenting with severe abdominal pain and elevated enzymes. - Severe allergic reactions, including angioedema or anaphylaxis. - Hepatic dysfunction, indicated by marked elevation of liver transaminases.

Before starting Glypvilo, clinicians should evaluate patient history and monitor specific clinical parameters to minimize risks. Certain conditions require dose adjustment or avoidance of the drug, and consider alternative therapy when necessary.

- Assess renal function; dose may need reduction in moderate impairment. - Review hepatic function; avoid use in severe liver disease. - Monitor for signs of pancreatitis, especially persistent abdominal pain. - Check for hypersensitivity reactions during the first weeks of therapy. - Evaluate cardiovascular status, as some patients may experience edema. - Use caution in elderly patients due to higher risk of dizziness.

Glypvilo can interact with other medicines that affect glucose metabolism or share metabolic pathways. Identifying and managing these interactions helps maintain therapeutic effectiveness and safety, especially when multiple antidiabetic agents are prescribed.

Avoid: - Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase vildagliptin exposure. - Combination with other DPP‑4 inhibitors, as additive effects can lead to hypoglycemia. - Use in patients with severe hepatic impairment (Child‑Pugh class C).

Use with caution: - Co‑administration with sulfonylureas; monitor for increased risk of hypoglycemia. - Concurrent use of insulin; dose adjustments may be necessary to avoid low blood glucose. - Treatment alongside diuretics or antihypertensives; monitor blood pressure and electrolytes.